Embrace Hydrogel Embolic System
Instylla, Inc. · Decision date Sep 3, 2026
What did the FDA decide?
FDA posted a 30-Day Notice for Instylla, Inc.'s Embrace Hydrogel Embolic System under PMA supplement P250003/S009, dated September 3, 2026. The decision is recorded as OK30, and the supplement reason is a process change affecting manufacturer, sterilizer, packager, or supplier. The statement describes approval for a change in minimum packaging configuration.
This supplement does not represent a new approval of the entire system. The source statement does not identify which packaging component changed, the previous or new minimum configuration, or any associated manufacturing site. Specific information about the exact changed item is absent from the available record.
FDA approval order statement
approval for a change in minimum packaging configuration
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 3, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250003/S009
- Regulatory pathway
- PMA supplement
- Applicant
- Instylla, Inc.
- Product code
- QVG
- Decision code
- OK30
- Decision date
- Sep 3, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Embolization Agent, Vascular.
- Applicant
- Instylla, Inc.
- Product code
- QVG
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250003. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250003 · Original PMA
Embrace(TM) Hydrogel Embolic System
P250003/S009 received
Application receipt date recorded by FDA.
P250003/S009 · FDA decision
30-Day Notice
P250003/S010 · Related supplement
Embrace(TM) Hydrogel Embolic System
P250003/S008 · Related supplement
Embrace(TM) Hydrogel Embolic System
P250003/S011 · Related supplement
Embrace Hydrogel Embolic System
Timeline entries are records held by MedtechLedger for P250003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Instylla, Inc. | PMA approval | Aug 5, 2025 | FDA | |
Embrace(TM) Hydrogel Embolic SystemP250003/S010 | Instylla, Inc. | PMA supplement | Oct 21, 2026 | FDA |
Embrace(TM) Hydrogel Embolic SystemP250003/S008 | Instylla, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Embrace Hydrogel Embolic SystemP250003/S011 | Instylla, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Instylla, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 201 Burlington Rd., North Bldg., Bedford, MA, 01730
Sources and methodology
- Original FDA record: P250003/S009
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
